Algorithm of treatment of patients with castrate-resistant prostate cancer: modern concept and perspectives

Abstract


Prostate cancer is one of the most actual problems of modern oncourology. Castrate-refractory prostate cancer (CRPC) is extremely he-terogeneous disease and treatment conception should be individualized in every patient. Therapeutic options in CRPC include 2nd line hormonal therapy, chemotherapy, vaccines, target therapy, radiopharmaceuticals, etc. However, clear algorithm of treatment in using of 1st or 2nd line drugs nowadays is absent. In the article modern concept of treatment of patients with CRPC is present, moreover prognostic factors of therapeutic response are analyzed.

Full Text

Restricted Access

About the authors

B Ya Alekseev

K M Nyushko

A S Kalpinskiy

A D Kaprin

References

  1. Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2012 г. М., 2013.
  2. Garnick M.B. Prostate cancer: screening, diagnosis, and management. Ann Intern Med 1993; 118: 804-18.
  3. Kantoff P.W, Halabi S, Conaway M et al. Hydrocortisone with or without mitoxantrone in men with hormone - refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 1999; 17: 2506-13.
  4. European Association of Urology Guidelines. 2013 ed.; p. 133.
  5. Oh W. Chemotherapy for patients with advanced prostate carcinoma: a new option for therapy. Cancer 2000; 88: 3015-21.
  6. Hoffman-Censits J, Fu M. Chemotherapy and targeted therapies: are we making progress in castrate - resistant prostate cancer? Semin Oncol 2013; 40 (3): 361-74.
  7. Manni A, Bartholomew M, Caplan R et al. Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome. J Clin Oncol 1988; 6 (9): 1456-66.
  8. Taylor C.D, Elson P, Trump D.L. Importance of continued testicular suppression in hormone - refractory prostate cancer. J Clin Oncol 1993; 11 (11): 2167-72.
  9. Hussain M, Wolf M, Marshall E et al. Effects of continued androgen - deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone - refractory prostate cancer: a Southwest Oncology Group report. J Clin Oncol 1994; 12 (9): 1868-75.
  10. Stein C.A. Mechanisms of action of taxanes in prostate cancer. Semin Oncol 1999; 26: 3-7.
  11. Fowler J.E Jr, Pandey P, Seaver L.E, Feliz T.P. Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment. J Urol 1995; 154: 448-53.
  12. Kucuk O, Fisher E, Moinpour C.M et al. Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235). Urology 2001; 58 (1): 53-8.
  13. Suzuki H, Okihara K, Miyake H et al. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol 2008; 180 (3): 921-7.
  14. European Association of Urology Guidelines. 2014 ed.; p. 155.
  15. Eisenhauer E.A, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (vers. 1.1). Eur J Cancer 2009; 45 (2): 228-47.
  16. Marcelli M, Ittmann M, Mariani S et al. Androgen receptor mutations in prostate cancer. Cancer Res 2000; 60: 944-9.
  17. Haapala K, Hyytinen E.R, Roiha M et al. Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide. Lab Invest 2001; 81: 1674-51.
  18. Scher H.I, Kelly W.K. Flutamide withdrawal syndrome: its impact on clinical trials in hormone - refractory prostate cancer. J Clin Oncol 1993; 11 (8): 1566-72.
  19. Small E.J, Carroll P.R. Prostate - specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 1994; 43 (3): 408-10.
  20. Dawson N.A, Mc Leod D.G. Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome. J Urol 1995; 153 (6): 1946-7.
  21. Attard G, Reid A.H, Yap T.A et al. Phase I clinical trial of a selective inhibitor of CYP-17, abiraterone acetate, confirms that castration - resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26 (28): 4563-71.
  22. Attard G, Reid A.H, A’Hern R et al. Selective inhibition of CYP-17 with abiraterone acetate is highly active in the treatment of castration - resistant prostate cancer. J Clin Oncol 2009; 27 (23): 3742-8.
  23. Danila D.C, Morris M.J, de Bono J.S et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxeltreated castration - resistant prostate cancer. J Clin Oncol 2010; 28 (9): 1496-501.
  24. Ryan C.J, Smith M.R, Fong L et al. Phase I clinical trial of the CYP-17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration - resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010; 28 (9): 1481-8.
  25. Reid A.H, Attard G, Danila D.C et al. Significant and sustained antitumor activity in post - docetaxel, castration - resistant prostate cancer with the CYP-17 inhibitor abiraterone acetate. J Clin Oncol 2010; 28 (9): 1489-95.
  26. de Bono J.S, Logothetis C.J, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364 (21): 1995-2005.
  27. Ryan C.J, Smith M.R, de Bono J.S et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368 (2): 138-48.
  28. Basch E, Autio K, Ryan C.J et al. Abiraterone acetate plus prednisone vs prednisone alone in chemotherapy - naive men with metastatic castration - resistant prostate cancer: patient - reported outcome results of a randomised phase 3 trial. Lancet Oncol 2013; 14 (12): 1193-9.
  29. Tannock I.F, de Wit R, Berry W.R et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351 (15): 1502-12.
  30. de Bono J.S, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration - resistant prostate cancer progressing after docetaxel treatment: a randomised open - label trial. Lancet 2010; 376 (9747): 1147-54.
  31. Aapro M.S, Bohlius J, Cameron D.A et al. 2010 update of EORTC guidelines for the use of granulocyte - colony stimulating factor to reduce the incidence of chemotherapy - induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011; 47 (1): 8-32; http://10.1016/j.ejca.2010.10.013
  32. Smith T.J, Khatcheressian J, Lyman G.H et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence - based clinical practice guideline. J Clin Oncol 2006; 24 (19): 3187-205.
  33. Loriot et al. J Clin Oncol 2012; 30 (Suppl. 5): Abstr. 213.
  34. Kantoff P.W, Higano C.S, Shore N.D et al. Sipuleucel-T immunotherapy for castration - resistant prostate cancer. N Engl J Med 2010; 363 (5): 411-22.
  35. Scher H.I, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367 (13): 1187-97.
  36. Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369 (3): 213-23.
  37. Smith D.C, Smith M.R, Sweeney C et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 2013; 31 (4): 412-9.
  38. Pili R, Häggman M, Stadler W.M et al. Phase II randomized, double - blind, placebo - controlled study of tasquinimod in men with minimally symptomatic metastatic castrate - resistant prostate cancer. J Clin Oncol 2011; 29 (30): 4022-8.
  39. Loriot et al. J Clin Oncol 2012; 30 (Suppl. 5): Abstr. 213.
  40. Oudard S et al. Progress in emerging therapies for advanced prostate cancer. Cancer Treat Rev 2013; 39 (3): 275-89.
  41. van Soest R.J, de Morrée E.S, Shen L et al. Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration - resistant prostate cancer treated with docetaxel. TAX327 Study. Eur Urol 2013; http://pii: S0302-2838(13)00828-2
  42. Fizazi K, Flaig Th, Carsten H et al. Does Gleason score predict efficacy of abiraterone acetate therapy in patients with metastatic castration - resistant prostate cancer? An analysis of abiraterone acetate phase 3 trials. Poster presented at the 2014 Genitourinary Cancers Symposium (ASCO GU). San Francisco 2014, CA.

Statistics

Views

Abstract - 18

Cited-By


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies